The 22nd Congress of the European Hematology Association (EHA) took place June 22-25, 2017, in Madrid, Spain.

KRD appears more active, less safe than KCD in newly diagnosed MM

Print Friendly, PDF & Email


Micrograph showing MM
New research suggests one triplet regimen may be more active but also more toxic than another in patients with newly diagnosed multiple myeloma (MM). In the FORTE trial, the combination of carfilzomib, lenalidomide, and dexamethasone (KRD) produced higher response rates than carfilzomib, cyclophosphamide, and dexamethasone (KCD). However, treatment with KRD... [Read Article]
Print Friendly, PDF & Email

Long-term maintenance deemed feasible in PV

Print Friendly, PDF & Email


Micrograph showing PV
Image courtesy of AFIP
Long-term maintenance with ropeginterferon alfa-2b is feasible, effective, and well-tolerated in patients with polycythemia vera (PV), according to researchers. In the ongoing phase 1/2 PEGINVERA study, patients have received ropeginterferon alfa-2b for a median of 4 years. After the first 2 years, patients switched from bi-weekly... [Read Article]
Print Friendly, PDF & Email

Combo may be option for elderly patients with untreated AML

Print Friendly, PDF & Email


Andrew Wei, MBBS, PhD
The combination of venetoclax and low-dose cytarabine (VEN+LDAC) appears to be a feasible treatment option for elderly patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. In a phase 1/2 study of such patients, VEN+LDAC was considered well-tolerated, conferring moderate myelosuppression and largely low-grade non-hematologic... [Read Article]
Print Friendly, PDF & Email

CTL019 produces responses in rel/ref DLBCL

Print Friendly, PDF & Email


Gilles Salles, MD, PhD
The chimeric antigen receptor (CAR) T-cell therapy CTL019 produced a high response rate in a phase 2 trial of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to researchers. An interim analysis of the JULIET trial revealed a 3-month overall response rate (ORR) of 45%. Thirty-seven percent of... [Read Article]
Print Friendly, PDF & Email

De-escalation may improve success of TKI cessation

Print Friendly, PDF & Email


Imatinib tablet cut
with a pill splitter
Photo by Patrick Pelletier
Results of the DESTINY trial suggest that chronic myeloid leukemia (CML) patients may improve their chances of successfully stopping treatment with tyrosine kinase inhibitors (TKIs) by first reducing the dose they receive. CML patients in deep molecular response (MR4) at study entry... [Read Article]
Print Friendly, PDF & Email

Luspatercept appears safe, effective in β-thalassemia

Print Friendly, PDF & Email


Blood for transfusion
Photo from UAB Hospital
Results of a phase 2 study have shown that luspatercept can produce sustained increases in hemoglobin and reductions in transfusion burden in adults with β-thalassemia. Some patients are still receiving the drug and experiencing clinical benefits beyond 24 months. Luspatercept has been well-tolerated in these patients,... [Read Article]
Print Friendly, PDF & Email

T-cell product improves outcomes of haplo-HSCT

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
Preliminary results of a phase 1/2 study suggest the T-cell product BPX-501 lowers the risks associated with haploidentical hematopoietic stem cell transplant (haplo-HSCT). In this ongoing study, researchers are testing BPX-501 in pediatric patients undergoing haplo-HSCT to treat a range of hematologic disorders. Patients treated thus far... [Read Article]
Print Friendly, PDF & Email

Less is more in PET-negative, advanced HL

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
Patients with advanced Hodgkin lymphoma (HL) who are PET-negative after initial treatment with 2 cycles of eBEACOPP* should only receive 2 additional cycles of the therapy, new research suggests. In the HD18 trial, PET-2-negative patients who received 4 cycles of eBEACOPP had non-inferior progression-free survival... [Read Article]
Print Friendly, PDF & Email